Therapeutic Antibodies: Advancing the Development of COVID-19 Neutralizing Antibodies

The COVID-19 pandemic has driven the need for the development of novel therapeutics targeting the coronavirus. Understanding the infection pathway of SARS-CoV-2 and how the immune system responds to the viral infection is essential in developing effective therapeutics. Early in the pandemic, scientists at Abwiz Bio began developing a potent neutralizing antibody to help in the fight against COVID-19 and have since developed a range of neutralizing antibodies that show broad neutralization of all variants to date (alpha, beta, gamma, delta, kappa, and mu). 

In this interview, the editors from selectscience speak with Kevin Entzminger, Director of Antibody Discovery and Engineering at Abwiz Bio, to learn more about how virus-neutralizing antibodies have proven to be a key tool in the fight against SARS-CoV-2, the advantages of using the Sartorius Octet^® R8 label-free protein analysis system in this work, and why science communication and collaboration between researchers is so important